Connect with us

BioPharma

Cybernetic Technologies Ltd (OTCMKTS: HPIL) Powerful Move Brewing as New CEO of CrankMedia Takes Control of the Company

Published

on

Cybernetic Technologies Ltd (OTCMKTS: HPIL) continues to move steadily higher with power in recent days with daily trading volumes regularly in the billions and $5 to $10 million in daily dollar volume is no big deal. HPIL has emerged in recent weeks as an investors favorite and is currently among the most actively searched and talked about stocks in small caps. Currently under heavy accumulation HPIL is moving steadily northbound with many new investors buying in every day. HIPL is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – HIPL is currently on a blue-sky breakout! 

HPIL has been making one big move after the other since top level music executive Stephen Brown of Crank Media who took his last Company from nothing to value at over $500 million on the NASDAQ took over the Company. HPIL officially changed its name to Cybernetic Technologies, Ltd. affected a major share reduction and joined forces with a group led by L. Ferrox Tutinean to launch Apogee Dynamics Ltd a company that Cybernetic Technologies is a majority owner. The Company was developed for the purpose of developing a battery power source that will never need charging while in use for such vehicles as Automobiles, Boats, and many other forms of transportation. 

Cybernetic Technologies Ltd (OTCMKTS: HPIL) operating out of Vancouver, Canada is a worldwide diversified company developing projects with cutting edge technology. New HPIL CEO Stephen Brown is the founder of a successful Independent Record label in the 90’s, Mr Brown went on to form a ground breaking streaming video company called Vidnet,with the vision that the Internet would eventually have a major position in the Music and Film distribution market. Vidnet became one of the top entertainment sites on the web, streaming over 5 million videos monthly and providing content to such companies as British Telecom, Microsoft, Disney, Lycos, Alta Vista and many more, along with industry alliances such as entertainment giants, Sony Music, Warner Bros and EMI Capital. Vidnet had one of the world’s largest collections of music videos on line. Mr Brown built the company from 5 to over 100 employees; and also took the company public on the NASDAQ, reaching a market cap of over $500M.  

Joining the HPIL executive team is David Postula as President. David is a seasoned senior executive with broad experience driving strategy, business optimization and revenue growth across a number of technology segments. He has a true passion for new technology and business strategy, which he brings to his role with Crank Virtual a division of Crank Media. Prior to joining Crank Virtual, David was Vice President of Strategy and Business Development for Tower Semiconductor, where he was responsible for driving strategy, roadmaps, and both customer & partner alliances in support of $1B of 2020/2021 Revenues. Before that, David was the Vice President of NA Sales at Global Foundries, where he co-created, implemented and executed a sales strategy that exceeded new customer and revenue targets by 20%. 

HPIL has recently aquried World Gaming Group Inc, who over the past 18 months have been involved in blockchain projects and have developed “GAMEZCASH” and “TUNEZCASH”  that are to be used as a new form of currency in the esports/gaming world and the online music industry. HPIL has also joined forces with a group led by L. Ferrox Tutinean to launch Apogee Dynamics Ltd a company that Cybernetic Technologies is a majority owner. The Company was developed for the purpose of developing a battery power source that will never need charging while in use for such vehicles as Automobiles, Boats, and many other forms of transportation. 

To Find out the inside Scoop on HPIL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

HPIL

They also acquired 100% of NFT Procurement Ltd an emerging leader in the highly luscrative NFT space that already owns a large datbase of domains including: nftmariolemieux.com nftsidneycrosby.com nftcindycrawford.com nftgiselebundchen.comnfttyrabanks.com nftkyliejenner.com nftjohnwayne.com nftfranksinatra.com nftsiegfriedandroy.com nftliberace.com nftthepope.com nftthewho.com nftledzeppelin.com nftpinkfloyd.com nftmoodyblues.com nftcoldplay.com nftozzyosbourne.com nftblackpanther.com nftconnormcdavid.com, nftladygaga.com nftspicegirls.com nftonedirection.com nftharrystyles.comftedsheeran.com nfttakethat.com nftrobbiewilliams.com nftgarybarlow.comnftalanfrew.com nftbobmarley.com nftjanisjoplin.com nftericclapton.comnftjimihendrix.com nftfettywap.com nftthekardashians.com nftaaronrogers.comnftkeithrichards.com nftbrettfavre.com nftmajicjohnson.com nftmichaelbuble.comnfttriumph.com nftbryanadams.com nftjohnlennon.com nftchadwickboseman.comnftgameofthrones.com nftvancouvercanucks.com nftstanleycup.com nftronniewood.comnftseinfeld.com nftdavidbowie.com nftprincecharles.com nftrodstewart.comnftmickjagger.com nftcharliewatts.com nftjoecocker.com nftdavidfoster.comnftjlo.com nftjenniferlopez.com nftgeorgeclooney.com nftjimmorrison.comnftchuckberry.com nftharrypotter.com nftpaulmccartney.com nftdavidbeckham.comnftbansky.com nftalpacino.com nftmerylstreep.com nfttorontomapleleafs.comnftbostonbruins.com nftmontrealcanadiens.com nftlakings.com nftpotus.com just to name a few. 

On June 22 HPIL announced it has decided to develop its own electric auto named “APOGEE D7” using the powertrain developed by L. Ferrox Tutinean and Apogee Dynamics Ltd. The plan for the new Apogee D7 is a 4-seater vehicle that will not only use the new Apogee powertrain it will have up to 10 partners all utilizing their DISRUPTIVE business models from Technology, Green, Materials and Media that will challenge the future of the auto industry as it is known today. All partners will have their imprint on the vehicle and will be an instrumental part of its functionality. We look to have the Apogee D7 website up within the next 45 days” said Stephen Brown CEO. 

For More on HPIL Subscribe Right Now!

HPIL continues to move steadily higher with power in recent days with daily trading volumes regularly in the billions and $5 to $10 million in daily dollar volume is no big deal. HPIL has emerged in recent weeks as an investors favorite and is currently among the most actively searched and talked about stocks in small caps. Currently under heavy accumulation HPIL is moving steadily northbound with many new investors buying in every day. HIPL is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – HIPL is currently on a blue-sky breakout! HPIL has been making one big move after the other since top level music executive Stephen Brown of Crank Media who took his last Company from nothing to value at over $500 million on the NASDAQ took over the Company. HPIL officially changed its name to Cybernetic Technologies, Ltd. affected a major share reduction and joined forces with a group led by L. Ferrox Tutinean to launch Apogee Dynamics Ltd a company that Cybernetic Technologies is a majority owner. The Company was developed for the purpose of developing a battery power source that will never need charging while in use for such vehicles as Automobiles, Boats, and many other forms of transportation. We will be updating on HPIL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HPIL.

Disclosure: we hold no position in HPIL either long or short and we have not been compensated for this article.

Continue Reading
1 Comment

1 Comment

  1. Diane S

    June 25, 2021 at 6:48 am

    Hi there are two places in the article where HPIL is spelled incorrectly. Other than that wow thank you for the article

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

on

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

on

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.